FDA panel votes against approving morphine-oxycodone opioid | Addiction Professional Magazine Skip to content Skip to navigation

FDA panel votes against approving morphine-oxycodone opioid

April 23, 2014
by Shannon Brys, Associate Editor
| Reprints

During a government panel hearing on Tuesday, the Food and Drug Administration (FDA) advisory committee unanimously voted against the approval of Moxduo, the first drug that combines morphine and oxycodone into one capsule, according to a report by NPR

According to the article:

The committee also voted unanimously that the drug's developer had not proved that Moxduo is less likely to cause potentially life-threatening respiratory suppression than taking morphine or oxycodone alone.

The claims previously made by the company that developed Moxduo, QRxPharma, said that "the drug would provide fast relief for millions of patients suffering from moderate to severe pain, including accident victims and people undergoing major surgery."

Addiction experts are concerned about the drug making it to the market as they say it is more likely to be abused than opioid drugs such as Vicodin and Percocet. 

Read the source article at NPR